Is Celldex Therapeutics, Inc. (CLDX) a Buy, Sell, or Hold?
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$38.17 USD
-$0.36 (-0.93%)
- Volume
- 702.07K
- Average Volume
- 959.49K
- Market Capitalization
- $2.54B
- P/E Ratio
- -8.94
- Dividend Yield
- 0.00%
- Price Target
- $48.00
- Year High
- $40.30
- Year Low
- $19.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.92
| Source | Headline |
|---|---|
|
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab's potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU. globenewswire.com - 2026-06-14 10:21:00 |
|
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP. globenewswire.com - 2026-06-14 05:15:00 |
|
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026. globenewswire.com - 2026-06-10 16:01:00 |
|
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N. J. , June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026. globenewswire.com - 2026-06-10 16:01:00 |
|
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago. zacks.com - 2026-05-07 18:55:22 |
|
Celldex Reports First Quarter Financial Results and Provides Corporate Update
HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. globenewswire.com - 2026-05-07 16:01:00 |
|
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's robust cash position ($518.6M at 2025 year-end, $345M raised in April 2026) supports operations through 2027, mitigating near-term dilution risk. Phase 3 enrollment for CSU completed six months early; top-line data expected Q4/26, with BLA filing planned for 2027. seekingalpha.com - 2026-05-07 08:55:54 |
|
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2026-05-04 10:56:05 |
|
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
Celldex Therapeutics (NASDAQ: CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an anti-KIT monoclonal antibody being developed for chronic urticaria and other inflammatory skin diseases, and to outline upcoming clinical milestones across the pipeline. Barzolvolimab positioned as mast-cell depleting approach In response defenseworld.net - 2026-04-15 03:35:11 |
